home / stock / fstx / fstx news

FSTX News and Press, F-star Therapeutics Inc Com From 03/10/22

Stock Information
Company Name: F-star Therapeutics Inc Com
Stock Symbol: FSTX
Market: NASDAQ
Menu
FSTX FSTX Quote FSTX Short FSTX News FSTX Articles FSTX Message Board
Get FSTX Alerts

News, Short Squeeze, Breakout and More Instantly...
FSTX - F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced...
FSTX - F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today...

FSTX - F-star Therapeutics Appoints James Sandy as Chief Development Officer

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today...

FSTX - F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3

Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-sta...
FSTX - F-star Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-generation bispecific immunotherapies to transform the lives of patients with cancer, today ann...

FSTX - F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today ann...

FSTX - F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today ann...
FSTX - Catalyst watch for next week: Rivian ratings pour in, big events for Southwest Airlines, McKesson and CVS Health

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

FSTX - F-star Therapeutics to Host Virtual R&D Day on December 6, 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today ann...

FSTX - F-star Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation

The following slide deck was published by F-star Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: F-star Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation

Previous 10 Next 10